Compensatory ErbB3/c-Src signaling enhances carcinoma cell survival to ionizing radiation
dc.contributor.author | Mikkelsen, Ross B. | en_US |
dc.contributor.author | Contessa, Joseph N. | en_US |
dc.contributor.author | Abell, Angela | en_US |
dc.contributor.author | Valerie, Kristoffer | en_US |
dc.contributor.author | Schmidt-Ullrich, Rupert K. | en_US |
dc.date.accessioned | 2006-09-11T14:28:47Z | |
dc.date.available | 2006-09-11T14:28:47Z | |
dc.date.issued | 2006-01 | en_US |
dc.identifier.citation | Contessa, Joseph N.; Abell, Angela; Mikkelsen, Ross B.; Valerie, Kristoffer; Schmidt-Ullrich, Rupert K.; (2006). "Compensatory ErbB3/c-Src signaling enhances carcinoma cell survival to ionizing radiation." Breast Cancer Research and Treatment 95(1): 17-27. <http://hdl.handle.net/2027.42/44234> | en_US |
dc.identifier.issn | 0167-6806 | en_US |
dc.identifier.issn | 1573-7217 | en_US |
dc.identifier.uri | https://hdl.handle.net/2027.42/44234 | |
dc.identifier.uri | http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=retrieve&db=pubmed&list_uids=16267617&dopt=citation | en_US |
dc.description.abstract | EGFR and ErbB2 are two members of the ErbB family of receptor Tyr Kinases identified as therapeutic targets for treating carcinomas. Breast carcinoma cells express different complements and variable proportions of ErbB receptor Tyr kinases, which activate unique and redundant signaling cascades that are essential for cell survival. Previously it was shown that a COOH-terminal truncation mutant of the EGFR (EGFR-CD533) blocks EGFR dependent signals and radiosensitizes breast carcinoma cells. In this study the effects of EGFR-CD533 and an analogous truncation mutant of ErbB2 (ErbB2-CD572) on ErbB receptor family dimerization and signaling are further investigated. Using adenoviral vectors in breast carcinoma cell lines with variable ErbB expression profiles, we demonstrate different effects for each deletion mutant. EGFR-CD533 blocks ligand stimulation of EGFR, ErbB2, and ErbB4, but is associated with a compensatory Tyr kinase activity resulting in phosphorylation of ErbB3. In contrast, ErbB2-CD572 produces a weaker, non-specific pattern of ErbB receptor family inhibition, based upon the ErbB expression pattern of the cell type. Investigation of the compensatory Tyr kinase activity associated with EGFR-CD533 expression identified an ErbB3/c-Src signaling pathway that regulates expression of anti-apoptotic Bcl family proteins. This signaling is active in the T47D cell line, which inherently over-express ErbB3, absent in MDA-MB231 cells, which have low ErbB3 expression levels, and is restored in a MDA-MB231 cell line engineered to over-express ErbB3. Furthermore we demonstrate that ErbB3/c-Src signaling is radio-protective, and that its elimination through pharmacologic inhibition of c-Src enhances radiation-induced apoptosis. In summary, these studies identify a novel ErbB3/c-Src survival signal and point to ErbB3 expression levels as an important variable in therapeutic targeting of ErbB receptors in breast carcinoma cells. | en_US |
dc.format.extent | 481362 bytes | |
dc.format.extent | 3115 bytes | |
dc.format.mimetype | application/pdf | |
dc.format.mimetype | text/plain | |
dc.language.iso | en_US | |
dc.publisher | Kluwer Academic Publishers-Plenum Publishers; Springer Science+Business Media, Inc. | en_US |
dc.subject.other | Apoptosis | en_US |
dc.subject.other | C-Src | en_US |
dc.subject.other | EGFR | en_US |
dc.subject.other | ErbB3/Her3 | en_US |
dc.title | Compensatory ErbB3/c-Src signaling enhances carcinoma cell survival to ionizing radiation | en_US |
dc.type | Article | en_US |
dc.subject.hlbsecondlevel | Internal Medicine and Specialties | en_US |
dc.subject.hlbsecondlevel | Neurosciences | en_US |
dc.subject.hlbsecondlevel | Public Health | en_US |
dc.subject.hlbsecondlevel | Obstetrics and Gynecology | en_US |
dc.subject.hlbsecondlevel | Otolaryngology | en_US |
dc.subject.hlbsecondlevel | Oncology and Hematology | en_US |
dc.subject.hlbsecondlevel | Ophthalmology | en_US |
dc.subject.hlbtoplevel | Health Sciences | en_US |
dc.description.peerreviewed | Peer Reviewed | en_US |
dc.contributor.affiliationum | The Department of Radiation Oncology, Medical College of Virginia/Virginia Commonwealth University, Richmond, VA, 23298, USA, ; Department of Radiation Oncology, University of Michigan, 1500 East Medical Center Drive, UH B2 C490, Box 0010, Ann Arbor, MI, 48109, USA, ; Department of Radiation Oncology, University of Michigan, 1500 East Medical Center Drive, UH B2 C490, Box 0010, Ann Arbor, MI, 48109, USA, | en_US |
dc.contributor.affiliationother | The Department of Radiation Oncology, Medical College of Virginia/Virginia Commonwealth University, Richmond, VA, 23298, USA, | en_US |
dc.contributor.affiliationother | The Department of Radiation Oncology, Medical College of Virginia/Virginia Commonwealth University, Richmond, VA, 23298, USA, | en_US |
dc.contributor.affiliationother | The Department of Radiation Oncology, Medical College of Virginia/Virginia Commonwealth University, Richmond, VA, 23298, USA, | en_US |
dc.contributor.affiliationother | The Department of Radiation Oncology, Medical College of Virginia/Virginia Commonwealth University, Richmond, VA, 23298, USA, | en_US |
dc.contributor.affiliationumcampus | Ann Arbor | en_US |
dc.identifier.pmid | 16267617 | en_US |
dc.description.bitstreamurl | http://deepblue.lib.umich.edu/bitstream/2027.42/44234/1/10549_2005_Article_9023.pdf | en_US |
dc.identifier.doi | http://dx.doi.org/10.1007/s10549-005-9023-9 | en_US |
dc.identifier.source | Breast Cancer Research and Treatment | en_US |
dc.owningcollname | Interdisciplinary and Peer-Reviewed |
Files in this item
Remediation of Harmful Language
The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.
Accessibility
If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.